Yesterday, Sept. 21, 2015, 51 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $156.10 to $22,260,300.00.

Highlighted Stocks Traded by Insiders:

Neurocrine Biosciences (NBIX) - FREE Research Report

Lyons Gary A, who is Director at Neurocrine Biosciences, sold 15,000 shares at $54.89 on Sept. 21, 2015. Following this transaction, the Director owned 252,066 shares meaning that the stake was reduced by 5.62% with the 15,000-share transaction.

The shares most recently traded at $49.51, down $5.38, or 10.86% since the insider transaction. Historical insider transactions for Neurocrine Biosciences go as follows:

  • 4-Week # shares sold: 30,000
  • 12-Week # shares sold: 30,000
  • 24-Week # shares sold: 30,000

The average volume for Neurocrine Biosciences has been 802,400 shares per day over the past 30 days. Neurocrine Biosciences has a market cap of $4.7 billion and is part of the health care sector and drugs industry. Shares are up 124.62% year-to-date as of the close of trading on Monday.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. Currently, there are 8 analysts who rate Neurocrine Biosciences a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBIX - FREE

TheStreet Quant Ratings rates Neurocrine Biosciences as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and feeble growth in the company's earnings per share. Get the full Neurocrine Biosciences Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Triangle Petroleum (TPLM) - FREE Research Report

Samuels Jonathan Ryan, who is President and CEO at Triangle Petroleum, bought 36,455 shares at $2.17 on Sept. 21, 2015. Following this transaction, the President and CEO owned 467,482 shares meaning that the stake was boosted by 8.46% with the 36,455-share transaction.

Bliffen Justin, who is Chief Financial Officer at Triangle Petroleum, bought 17,500 shares at $2.08 on Sept. 21, 2015. Following this transaction, the Chief Financial Officer owned 200,005 shares meaning that the stake was boosted by 9.59% with the 17,500-share transaction.

The shares most recently traded at $1.85, down $0.23, or 12.59% since the insider transaction. Historical insider transactions for Triangle Petroleum go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 20,000

The average volume for Triangle Petroleum has been 1.4 million shares per day over the past 30 days. Triangle Petroleum has a market cap of $152.5 million and is part of the basic materials sector and energy industry. Shares are down 62.97% year-to-date as of the close of trading on Monday.

Triangle Petroleum Corporation, an independent energy company, explores for, develops, and produces oil and natural gas resources primarily in the Bakken Shale and Three Forks formations in the Williston Basin of North Dakota and Montana. Currently, there is 1 analyst who rates Triangle Petroleum a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TPLM - FREE

TheStreet Quant Ratings rates Triangle Petroleum as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Triangle Petroleum Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Hurco Companies (HURC) - FREE Research Report

Porter Richard R., who is Director at Hurco Companies, bought 1,000 shares at $27.64 on Sept. 21, 2015. Following this transaction, the Director owned 6,218 shares meaning that the stake was boosted by 19.16% with the 1,000-share transaction.

The shares most recently traded at $28.14, up $0.50, or 1.78% since the insider transaction. Historical insider transactions for Hurco Companies go as follows:

  • 4-Week # shares bought: 750
  • 12-Week # shares bought: 750
  • 24-Week # shares bought: 750

The average volume for Hurco Companies has been 26,400 shares per day over the past 30 days. Hurco Companies has a market cap of $183.9 million and is part of the technology sector and electronics industry. Shares are down 16.02% year-to-date as of the close of trading on Monday.

Hurco Companies, Inc., an industrial technology company, designs, manufactures, and sells computerized machine tools for the companies in metal cutting industry primarily in North America, Europe, and the Asia Pacific. The stock currently has a dividend yield of 1.14%. The company has a P/E ratio of 11.4. Currently, there are no analysts who rate Hurco Companies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HURC - FREE

TheStreet Quant Ratings rates Hurco Companies as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Hurco Companies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.